Citi Sees a More Supportive Backdrop Forming for AbbVie (ABBV) and Biopharma

On January 27, Citi modestly chopped its terms people connected AbbVie Inc. (NYSE:ABBV) to $230 from $235 portion leaving its Neutral standing unchanged. The accommodation was portion of the firm’s broader Q4 reappraisal of the biopharma space. In its note, Citi said expectations crossed the assemblage look manageable, with net that could travel successful amended than feared, and added that little policy-related hazard could make a much supportive backdrop for the radical successful 2026.

At the aforesaid time, AbbVie faced immoderate disappointing objective news. According to a January 16 Reuters report, AbbVie and its spouse Genmab said their humor crab cause epcoritamab failed to amusement a wide endurance payment successful a late-stage study. The proceedings enrolled 483 patients with relapsed oregon refractory diffuse ample B-cell lymphoma who had already been treated astatine slightest erstwhile and were not eligible for intensive chemotherapy followed by a stem compartment transplant.

While patients connected the cause did not unrecorded longer successful a statistically meaningful mode astatine the clip of the analysis, the survey did present immoderate encouraging signals. The companies said much patients saw their crab go undetectable, responses lasted longer, and the clip earlier needing different attraction improved. AbbVie and Genmab said they program to reappraisal the information with regulators and stock further results astatine upcoming aesculapian conferences.

Epcoritamab is already approved successful respective countries for different lymphoma indications. It is sold arsenic Epkinly successful the U.S. and Japan, and arsenic Tepkinly successful the European Union.

AbbVie Inc. (NYSE:ABBV) is simply a planetary biopharmaceutical institution focused connected discovering, developing, and bringing caller medicines to market.

While we admit the imaginable of ABBV arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 13 Companies that Just Started Paying Dividends and 14 High Yield Dividend Stocks with Sustainable Payouts

Disclosure: None.